Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 When Administered to Adults With TB Disease.

Next Previous
Trial Profile

Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 When Administered to Adults With TB Disease.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 692342 (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Acronyms TUBERCULOSIS-017
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 30 Apr 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
  • 24 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 13 Feb 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top